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A B S T R A C TObjective: To inform policymakers of the importance of evaluating
various methods for estimating the direct medical expenditures for a
low-incidence condition, head and neck cancer (HNC). Methods: Four
methods of estimation have been identiﬁed: 1) summing all health care
expenditures, 2) estimating disease-speciﬁc expenditures consistent
with an attribution approach, 3) estimating disease-speciﬁc expendi-
tures by matching, and 4) estimating disease-speciﬁc expenditures by
using a regression-based approach. A literature review of studies (2005–
2012) that used the Medical Expenditure Panel Survey (MEPS) was
undertaken to establish the most popular expenditure estimation
methods. These methods were then applied to a sample of 120
respondents with HNC, derived from pooled data (2003-2008). Results:
The literature review shows that varying expenditure estimation
methods have been used with MEPS but no study compared and
contrasted all four methods. Our estimates are reﬂective of the national
treated prevalence of HNC. The upper-bound estimate of annual directsee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2013.10.004
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ndence to: Diarmuid Coughlan, Department of Econ
land.medical expenditures of adult respondents with HNC between 2003
and 2008 was $3.18 billion (in 2008 dollars). Comparable estimates
arising from methods focusing on disease-speciﬁc and incremental
expenditures were all lower in magnitude. Attribution yielded annual
expenditures of $1.41 billion, matching method of $1.56 billion, and
regression method of $1.09 billion. Conclusions: This research dem-
onstrates that variation exists across and within expenditure estima-
tion methods applied to MEPS data. Despite concerns regarding aspects
of reliability and consistency, reporting a combination of the four
methods offers a degree of transparency and validity to estimating
the likely range of annual direct medical expenditures of a condition.
Keywords: direct medical expenditures, econometrics, head and neck
cancer, matching, Medical Expenditure Panel Survey.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
State and federal health policy makers often seek some estimate
of the economic burden of a disease to inform decisions regard-
ing resource allocation for prevention or treatment. With differ-
ent budgetary responsibilities, the needs for and uses of such
data will vary. Regardless, a cost-of-illness (COI) study is the main
vehicle for arriving at such estimates [1]. These studies usually
include a combination of health care and related resource use,
productivity losses, and “intangible” burden related to quality of
life [2]. The perspective and methodology used can greatly affect
cost estimates [3] and varies between studies. The speciﬁcation of
what constituted “cost” is an important consideration—Does cost
translate to “charges” from providers or “expenditures” reim-
bursed by payers? [4] In the absence of guidelines or well-
accepted standards on the methods for COI studies, there is a
clear need to inform policymakers and other researchers of thedifferent approaches and the subsequent interpretation of results
[4]. Indeed, a review of asthma cost studies in the United States
shows that a 10-fold range in medical and nonmedical estimates
has been reported [5]. Despite numerous limitations, COI studies
remain popular and are often quoted in the mass media to
highlight the magnitude of a particular problem.
This article focuses on analyzing the direct medical expenditures
component of a COI estimate for a relatively low-incidence, but
topical condition— head and neck cancer (HNC). Because a subset of
HNCs is caused by the human papilloma virus (HPV), the economic
burden of HNC is likely to contribute to the HPV vaccination debate
[6]. Previous economic studies of HNC were derived from nonna-
tionally representative sources—Surveillance, Epidemiology, and
End Results–Medicare [7] and managed-care population [8].
The Medical Expenditure Panel Survey (MEPS), with a nation-
ally representative respondent population, is commonly used
for the purpose of generating a COI estimate [9]. Based onociety for Pharmacoeconomics and Outcomes Research (ISPOR).
omics, St. Mary’s Building, University Road, National University of
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the MEPS is an appealing data source for analysts intent on
informing public policy. The MEPS can link information on
individuals and households to their use of and expenses for
health care. That the data is publicly available, components of
care are often veriﬁed, and a standardized metric of cost is used
make MEPS particularly useful [4]. A systematic review of COI
studies suggests a typology to describe the direct medical expen-
ditures of any disease: 1) the sum of all medical expenditures;
2) the sum of all disease-speciﬁc expenditures for a person with
the disease; 3) the difference in total expenditures between a
group of individuals with a disease and a matched sample of
those with similar characteristics; and 4) the incremental expen-
ditures associated with a disease estimated by using a regression-
based approach that includes an indicator comparing individuals
with and without the disease [1]. Staff members at the Agency
for Healthcare Research and Quality (AHRQ), which conducts the
MEPS, have previously discussed methodological issues related to
estimating the COI of diabetes [10] and obesity [11]. Given the lack
of strict COI guidelines when using the MEPS, we undertook a
literature review of recent MEPS studies to instruct our estimation
methodology.Literature Review
This review of the MEPS literature pertains to studies that report
health care expenditure estimates. The following search terms
were used: In PUBMED: (“methods” [MeSH terms] OR “method”
[text word] OR “economics” [Mesh] AND [“Medical expenditure
panel survey” OR “MEPS”]) and EMBASE: (“cost analysis”/exp OR
“cost analysis” AND “Medical expenditure panel survey”). Other
databases searched were Econlit, Web of Science, and Tufts CEA
Registry. Our inclusion criteria consisted of articles that repor-
ted an annual per-respondent direct medical expenditure for a
speciﬁc disease/condition between 2005 and 2012. The informa-
tion elicited from available articles included the following: 1)
direct medical expenditure estimating method as a subject of
“validity,” 2) model speciﬁcation/diagnostic tests as a subject of
“reliability,” and 3) comorbidity measure as a subject of
“consistency.”
Thirty-eight studies met our inclusion criteria [5,10,12–47].
The review highlighted considerable heterogeneity in the meth-
ods used to estimate the direct medical expenditures associated
with a condition. A detailed systematic review of COI studies
that use the MEPS is warranted. No MEPS health care expendi-
ture study reported a range of estimates using all four COI
methods. Only eight studies reported estimates using more than
one of these methods [10,14,17,19,24,40,41,47]. Regression mod-
els were the most popular method (31 studies) of estimating the
effect of a condition on health care expenditures [5,10,12–46].
Five studies reported condition-speciﬁc expenditures [14,18,39–
41] (attribution approach), and two studies used disease-related
events to identify patients [13,31]. Three studies used just a
matching approach [25,34,35], and ﬁve studies reported the
summation of all medical expenditures associated with a con-
dition approach [17,20,21,23,24]. There was considerable meth-
odological heterogeneity among the regression models. For just
positive expenditures, the generalized linear model (GLM) log
link and gamma distribution [5,12,14,17,18,32,36,40–46] (14 stud-
ies) was the most popular method followed by the logarithm of
expenditures in an ordinary least squares regression (9 studies)
[10,13,20,30,31,37,38,42,43]. Of the GLM studies, only eight
made reference to model speciﬁcation and diagnostic tests
[5,14,17,32,33,36,44,46].
In total, 26 studies accounted for comorbidities or made some
type of risk adjustment [5,10,13,14,16,18,20,22–46]. Such methodsincluded accounting for speciﬁc medical conditions, creating a
count of chronic diseases, or using the Charlson comorbidity
index. It has also been argued that theoretically comorbidities
should be equally prevalent in populations of people with and
without certain stand-alone diseases [40].
In conclusion, this literature review highlights issues with
the validity of the estimation methods used, the reliability of the
models developed in the absence of speciﬁcation tests, and the
lack of consistency in accounting for comorbidity. Methodologies,
however, are becoming more sophisticated—use of instrumental
variables [46] and the combination of matching and regression [5]
to derive an estimate are novel and likely to be replicated with
future MEPS expenditure estimation studies.Case Study: HNC and the MEPS
A detailed description of the survey can be found elsewhere [48]
and on the MEPS Web site. Brieﬂy, the MEPS collects data on
expenditures related to medical events such as inpatient stays,
outpatient, emergency room and ambulatory visits, and pre-
scribed medicines. In addition to household interviews, the MEPS
includes a medical provider component, a follow-back survey
that collects expenditure data from a sample of medical pro-
viders used by survey participants and is considered to be more
accurate than a household survey and given priority in expendi-
ture estimation [49]. Information on speciﬁc medical conditions is
obtained in the MEPS interview by asking respondents which
“health problems” had “bothered” each household member dur-
ing the observation period. Also, respondents report the reason
for each medical event. This method identiﬁes respondents with
HNC, which results in an estimate of the annual “treated
prevalence.” This would be distinct from incidence (establishing
phase-of-care expenditures) and prevalence (which includes
long-term survivors expenditures) cost-of-care estimates. The
Clinical Classiﬁcation Software system, a tool for clustering the
approximately 17,000 International Classiﬁcation of Diseases, Ninth
Revision condition codes into 285 mutually exclusive and homo-
geneous categories, was used to identify respondents with HNC
(Clinical Classiﬁcation Software ¼ 11).
As the annual number of cases of HNC in MEPS is smaller
than the 100 observations that the AHRQ suggests for making
national estimates, 6 years of data (2003–2008) were pooled to
generate an analytic sample [50]. In this case, the “pooled weight”
is the yearly person weight divided by the number of years (i.e.,
6). All expenditures were inﬂation adjusted to 2008 dollars by
using the medical component of the Consumer Price Index. MEPS
pooled data produce “average annual” estimates based on “per-
son-years.” This is because the same respondent can be observed
in 2 years of consolidated year ﬁles. Total expenditures for a
medical event are deﬁned as the sum of direct payments made by
all payers.
SAS software, version 9.3 (SAS Institute, Inc., Cary, NC), and
Stata software, version 11.2 (StataCorp, College Station, Texas),
were used for statistical analyses. The analyses incorporated
MEPS person-level weights and variance adjustment weights
(strata and primary sampling unit) that enable estimates to be
nationally representative.
Method 1: Identify All Patients with Diagnosis and Sum
Medical Expenditures
The objective is to identify respondents with the condition and
sum their medical expenditures. We considered the “treated
prevalence” as being those who have a diagnosis of HNC with
any medical event. We consider this to be the middle ground
between respondents who have reported a diagnosis of HNC
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speciﬁc medical events, who have been referred to as “affected
prevalence” in a study on cancer survivors [35]. This method is
straightforward but provides an estimate of all expenditures with
HNC rather than isolating the costs speciﬁcally due to the
disease; this necessarily overestimates expenditures attributable
to HNC.Method 2: Sum Disease-Speciﬁc Medical Expenditures
(Attribution)
This method restricts its attention to medical expenditures
related to the disease of interest. In the MEPS, this is achieved
by using the consolidated ﬁle, the condition ﬁle, condition-event
link, and events ﬁles including inpatient, emergency room,
outpatient, ofﬁce-based, home health, and pharmacy. We there-
fore deﬁned an HNC “case” as an adult with an HNC (Clinical
Classiﬁcation Software ¼ 11)-speciﬁc medical expenditure as
per AHRQ MEPS workshop notes. (For more details, please
contact the corresponding author). This method may under-
estimate the direct medical expenditures because it fails to
include “spillover costs” attributed to a speciﬁc condition. An
example of a spillover cost in cancer care would be a medical
visit for chemotherapy-induced nausea, which will be coded as
nausea and therefore unknown to the analyst to be cancer-
related [51]. Undoubtedly, other medical expenditures (e.g.,
mental health issues) are attributable to a respondent’s cancer.
Given that we did not ﬁnd any reliable epidemiologic estimates
in the literature, we essentially did not attribute any expenditure
fraction of other conditions to HNC.Method 3: Estimates Incremental Expenditures by a Matching
Approach
Comparing the medical expenditures of those with and those
without the disease and attributing the differences in medical
expenditures to the disease is logical. The essential difﬁculty,
however, is ﬁnding a control group that is reasonably compara-
ble. The objective of matching is to create a control that is
“balanced” with the case on the covariates. Matching variables
should be related to the condition (e.g., HNC) and the outcome
(e.g., total medical expenditure) [52]. There is little guidance/
consensus on how to speciﬁcally implement matching analyses
with total expenditure as the dependent variable. The general
advice is to think carefully about the set of covariates to include
in the matching procedure and err on the side of including more
rather than fewer [52]. Because expenditures are payments,
covariates that may be related to a respondent’s ability to pay
for treatment should be included in the matching algorithm.
Inherently, this approach introduces a degree of subjectivity into
the estimate.
The matching variables used in the reported analyses are age,
sex, race, insurance status (proxy for ability to pay), number of
priority medical conditions (proxy for comorbidity), and year of
data collection. All variables were given equal weight, and we
allowed a 7-year age gap between cases and controls to ensure
that a full 1:1 match was achieved. The legitimacy of using survey
population weights in making national estimates, however, is
debatable, with arguments existing around whether weights are
meaningful in the context of matched samples [25].
GMATCH [53], a nearest neighbor matching routine with-
out replacement (controls allowed to be used as a match only
once) in SAS, commonly known as “Greedy Matching,” was used
in this analysis. GMATCH goes through the cases one at a time
and picks the best control match on the basis of deﬁned
characteristics.Method 4: Estimate Incremental Expenditures Using a
Regression-Based Approach
The Andersen [54] conceptual model of health services utilization
is a popular organizing framework. An example of a MEPS study
that uses this model looks at serious psychological distress [26].
The model suggests that an individual’s utilization of health
services is a function of predisposing (e.g., age, sex, race/ethnic-
ity, and education), enabling (e.g., poverty category, insurance,
and region), and need (e.g., self-reported health status, number of
priority chronic conditions, and smoking status) factors. Health
care expenditures pose particular challenges for econometric
modeling. The distribution of strictly positive expenditures is
typically skewed, kurtotic, and heteroskedastic [55]. A variety of
models have been used to analyze expenditure/cost data, with
many analysts now presenting more than one model in their
reports [56,57]. We report the most popular MEPS regression
model, GLM. This is a popular approach to modeling health care
expenditures but not without its limitations [58].
The GLM framework requires a link function that relates the
conditional mean to the covariates and a distribution, to specify
the relationship between the variance and the mean [59]. The most
popular speciﬁcation of the GLM for health care expenditures has
been the log-link (Equation 1) with a gamma distribution (variance
proportional to the square of the mean; λ ¼ 2 in Equation 2) [60].
E yjx ¼f x′βð Þ¼exp x′βð ÞIn E yjx  ¼x′β ð1Þ
yVarðyjxÞ  E yjx  λ ð2Þ
We conducted diagnostic tests by using the “glmdiag” pro-
gram [61] that performs the recommended modiﬁed Park test for
the GLM family and the Pearson correlation test (checks for
systematic bias in ﬁt on raw scale), the Pregibon link test (checks
linearity of response on scale of estimation), and the modiﬁed
Hosmer and Lemeshow test (checks for systematic bias in ﬁt on
raw scale) for the GLM link [62]. The incremental expenditures
were calculated by using the method of “counterfactual regres-
sion predictions,” giving an attributable expenditure ﬁgure based
on the difference between the entire sample having HNC and no
respondent having HNC [60]. This attributable expenditure esti-
mate is then multiplied by the population weight to give the
national estimate of direct medical expenditures.Results
The annual number of respondents who self-reported to have HNC
in the MEPS data set (12–30 respondents per year, pooled ¼120) is
small relative to the number of respondents in the survey (30,000
respondents per year, pooled ¼ 191,407). The “treated prevalence”
consists of respondents with a medical expense in a given year—
113 person-year cases. Of these, two respondents were children.
We considered only adults in our analytic sample (see Table 1).
Using our interpretation, the “treated prevalence” refers to 111
“person-year” cases, and the “affected prevalence” (HNC–speciﬁc
expenditures) refers to 105 “person-year” observations. Therefore,
6 observations that reported to have HNC had medical events that
were not related to HNC.
Total Expenditures: Methods 1 and 2
The national direct medical expenditure by method 1 was $3.18
billion compared to $1.41 billion by method 2. The other reportable
information using MEPS data is the nature of health care utiliza-
tion and the type of payer. Figure 1A,B shows that ambulatory care
(ofﬁce-based and outpatient visits) is the most common medical
event. The mean HNC-speciﬁc ambulatory visit expenditure is
$395 (95% conﬁdence interval [CI] $329–$461). We note that
Table 1 – Comparison of demographic characteristics in MEPS adult respondents (>18 y) with and without head
and neck cancer (2003–2008).
Head and neck cancer (N ¼ 111) General adult sample (N ¼ 131,041) P
Age (y), mean  SE 63.21  1.11 46.16  0.05 o0.0001
Sex o0.0001
Male 76 (68) 59,850 (46)
Female 35 (32) 71,191 (54)
Race 0.474
White 89 (80) 100,338 (77)
Black 18 (16) 20,922 (16)
Asian 3 (3) 6,261 (5)
Other 1 (1) 3,520 (3)
Ethnicity o0.0001
Hispanic 6 (5) 31,019 (24)
Non-Hispanic 105 (95) 100,022 (76)
Education 0.665
No degree 29 (26) 31,062 (24)
GED/high school diploma 56 (50) 63,609 (49)
Bachelor degree or higher 26 (23) 35,608 (27)
Employment o0.0001
Not employed 67 (60) 43,966 (34)
Employed 39 (35) 85,451 (65)
Poverty 0.406
Poor 22 (20) 21,841 (17)
Near poor 10 (9) 7,825 (6)
Low income 16 (14) 21,108 (16)
Middle income 26 (23) 38,541 (29)
High income 37 (33) 41,726 (32)
Metropolitan statistical areas (MSA) o0.0001
Non-MSA 25 (23) 23,185 (18)
MSA 81 (73) 106,502 (81)
Region o0.0001
West 17 (15) 33,987 (26)
Northeast 13 (12) 19,788 (15)
Midwest 22 (20) 25,794 (20)
South 54 (49) 50,118 (38)
Health insurance o0.0001
Uninsured 1 (1) 24,905 (19)
Public only 50 (45) 80,433 (61)
Any private 60 (54) 25,703 (20)
Self-reported health status o0.0001
Poor/fair 49 (44) 20,334 (16)
Good/very good/excellent 50 (45) 108,863 (83)
Not ascertained 12 (11) 1,844 (1)
No. of priority chronic conditions o0.0001
0 30 (27) 71,469 (55)
1–2 46 (41) 45,327 (35)
3–5 25 (23) 12,872 (10)
6þ 10 (9) 1,373 (1)
Currently smoking 0.867
No 82 (74) 94,110(72)
Yes 20 (18) 24,685 (19)
Not ascertained 9 (8) 12,246 (9)
Sum of weights 215,662 219,364,212
Note. Values are n (%) unless indicated otherwise.
GED, General Educational Development; MEPS, Medical Expenditure Panel Survey; SE, standard error.
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than 40% of expenditures in this sample. The mean HNC-speciﬁc
inpatient expenditure is $13,291 (95% CI $3,212–$23,369).
With MEPS, policymakers can get an understanding of the
economic burden and plan accordingly. For HNC-related events,
more than 40% is paid for by private health insurance and
Medicare accounts for 35% of expenditures (Fig. 1C).Incremental Expenditures: Matching Approach (Method 3)
Our deﬁnition of “treated prevalence” takes into account any
medical event and not just disease-speciﬁc expenditures. Most
MEPS analyses consider the incremental expenditure approach to
be estimates based on respondents who reported the condition of
interest. The literature review, however, also highlighted two
Fig. 1 – There were 978 events associated with head and
neck cancer. (A) % by event type, (B) % by expenditure
amount, and (C) the distribution of HNC events by payer.
Code: AMBU, ambulatory visits (outpatient and ofﬁce-based
medical provider visits); EROM, emergency room visits;
HVIS, home health visits; IPAT, hospital inpatient stay;
PMED, prescription medicine.
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as their analytic sample for incremental expenditures [13,31].
Table 2 shows the difference in expenditures between the
groups attributed to the presence of HNC. Seven controls had $0
expenditures, and the largest annual expenditure of a control
observation was $64,042. In comparison, the expenditure for
cases ranged from $193 to $108,500.
Incremental Expenditures: Regression Approach (Method 4)
The reported GLM regression estimate (Table 3) is based on a
complete case analysis where all cases had positive expenditures.
The modiﬁed Park test indicated that the expenditure variable
followed a Poisson distribution. (Variance is proportional to
mean, λ ¼ 1 in Equation 2.) The log-link function, however,
yielded signiﬁcant P values for the Pearson correlation test, the
Pregibon link test, and the Hosmer and Lemeshow test. There is
no single test that identiﬁes the appropriate link, and we would
ideally hope that all the three tests would be consistent in
yielding nonsigniﬁcant P values [62]. The GLM “counterfactual
regression predictions” method put the incremental cost attrib-
utable to HNC at $5069 (95% CI $4481–$5658) per person. Extrap-
olating to the national population by using the pooled weights in
the MEPS for each respondent with HNC, the “average annual”
total medical expenditures were calculated to be $1.09 billion.Table 2 – Matching of head and neck cancer cases based
N Mean 95% con
HNC cases 111 $14,733 $13
Controls 111 $7,482 $6
HNC, head and neck cancer; MEPS, Medical Expenditure Panel Survey.
* Age, sex, race, insurance status, number of priority medical conditions
† Used survey weights from cases to generate a national estimate.Discussion
We report the results of four methods of estimating the direct
medical expenditures for a condition using the MEPS nationally
representative data set. According to our analyses, the average
annual (from 2003 to 2008), direct medical expenditures for adults
with HNC are in the range of $1.09 to $3.18 billion (in 2008
dollars). The National Cancer Institute (NCI) reports that HNC has
an annual treatment cost of $3.64 billion (2010 US dollars) [63].
The NCI estimate is based on an incidence phase-of-care
approach, and annualized costs were estimated from Surveil-
lance, Epidemiology, and End Results–Medicare linkage data [64].
Although there are no gold standard data sources for estimating
the prevalence costs of cancer care, the use of the MEPS for
national estimates has serious limitations associated with small
sample size [65]. The intention of this study, however, was to
highlight the reliability of expenditure estimates with respect to
methodological variation.
Method 1 gives an upper-bound estimate of $3.18 billion per
year. Because this method does not identify the incremental
expenditures attributable to HNC, it is not directly comparable to
the other approaches, a fact that policymakers must bear in
mind. As noted in a study on rheumatoid arthritis, the unad-
justed means are likely to be a multiple of the incremental health
care expenditures [19]. Methods 2 to 4 attempt to estimate the
additional health care costs associated with a condition and are
more directly comparable. How they do this though varies, as
noted in the discussion of the methods, a fact that may affect the
estimates produced and their subsequent interpretation. Method
2 captures only disease-speciﬁc events that have been recorded.
We noted that coding of MEPS medical events might be associ-
ated with more than one condition and that without accounting
for this duplicating of expenditures, spurious “double counting”
can occur. Estimates of cancer-attributable spending based on
the identiﬁcation of cancer-related encounters, however, are
subject to coding errors—for example, chemotherapy-induced
nausea. For this reason, statistical models (methods 3 and 4) do
not rely on diagnosis or procedure coding, and instead compare
expenditures between individuals [66]. We argue that the impor-
tance of capturing the speciﬁc disease-linked events (method 2) is
that it identiﬁes the affected prevalence and the nature of the
disease burden. In MEPS, ambulatory care is the most common
type of medical event (857 of 978, 87%) associated with HNC.
Inpatient care, however, accounts for 40% of expenditures based
on 20 events (2%), and private health insurance (41%) shoulders
the majority of the ﬁnancial burden in HNC.
For a low-incidence condition such as HNC, it is reasonable to
assume that all expenditures other than dental that are directly
attributable to the cancer are captured in the MEPS. We would
expect this method to set a lower bound, because it does not
capture any of the “spillover” or indirect medical expenditures
associated with the disease, which an incremental expenditure
would capture. For a condition with many secondary effects such
as diabetes, epidemiologic formulas based on attributableon MEPS variables*.
ﬁdence interval Mean difference in expenditure
and national estimate
,557–$15,909 $7,251
,551–$8,413 $1.81 billion†
, and year of data collection using the GMATCH routine.
Table 3 – Summary of results from the four cost-of-illness methods.
No. of
observations
Per “person-year”
mean*  SE
Direct medical expenditure
national estimate*
Total expenditures
Method 1: Sum all medical costs 111 $14,733  $2,006 $3.18 billion
Method 2: Disease-speciﬁc medical costs 105 $6,884  $1,600 $1.41 billion
Incremental expenditures
Method 3: Matching GMATCH 1:1 111 $7,251  $450 $1.56 billion
Method 4: Regression GLM – Log-link and Poisson
distribution†
111 $5,069  $3,614 $1.09 billion
GLM, generalized linear model; MSA, Metropolitan statistical areas; SE, standard error.
* US 2008 dollars.
† Covariates included in regression analysis: age, sex, race, ethnicity, education, employment, poverty status, MSA, region, health insurance,
self-reported health status, number of priority chronic conditions, and currently smoking.
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annual expenditures [14]. In the case of asthma, the MEPS
disease-speciﬁc estimate is 39% of the regression-based estimate
of the incremental direct cost of asthma in 2006 [32].
The incremental expenditure approach requires subjective
judgment regarding the speciﬁcation of the model to be used,
which may potentially lead to serious bias in both over- and
underestimating expenditures. The likelihood that selection bias
associated with undiagnosed HNC will materially affect results is
very low. It is unlikely that those with undiagnosed HNC would
have utilization patterns distinct from those of patients without
HNC because early diagnosis of HNC is often missed because of
the nonspeciﬁc symptoms or symptoms commonly associated
with benign conditions [67]. The GMATCH matching routine is
practical when variables are measured as discrete values. We
chose to match all cases in this analysis and gave each matching
variable equal weight. While this is acceptable, it is not the only
and may not be the optimal approach to analyze these data.
Further research could compare other algorithms and test the use
of MEPS population survey weights as a matching variable.
Although GMATCH is a freely available SAS program, more
sophisticated routines exist in R and STATA that use caliper or
kernel density matching with propensity scores. Additional
research using the MEPS data set could compare the various
techniques within matching to see what difference they make to
the reliability of an expenditure estimate.
Speciﬁcations of regression models are often based on a
conceptual framework such as the Andersen model of health
services utilization. Categorical measures of self-reported health
status have been shown to be good predictors of the subsequent
use of medical care and are included in our analyses [68]. Indeed,
the case for health status as the source of latent heterogeneity in
health care use is strong [69]. As seen in Table 1, there are large
differences among those with and without HNC in a number of
variables including self-reported health status and the number of
“quality priority conditions” (QPCs). Patients with cancer typically
have more comorbidities than do those without [70,71]. Therefore,
the mean annual expenditure of respondents with HNC ($14,733)
is likely to consist of a number of other conditions and not just this
cancer. In our analysis, we constructed a proxy for comorbidity by
using a count of QPCs. We chose this method because it is the
most straightforward to implement. Prescribing consistency when
adjusting for comorbidity is difﬁcult, because no single comorbid-
ity measurement appears to be the best predictor of health care
expenditure [72]. We argue that some measure is needed and that
using the count of QPCs as a proxy for comorbidity can at least be
applied across MEPS expenditure studies quite easily.
A lack of detail on the justiﬁcation for regression-based models
was noted in the literature review. In recent years, GLM is thepreferred regression method among MEPS analysts. In our analy-
sis, the modiﬁed Park test indicated that the GLM use a Poisson
distribution. The literature review showed that only one other
study used a Poisson distribution as dictated by model diagnostics
[33]. The speciﬁcation tests (Link test, Pearson test, and Hosmer
and Lemeshow test), however, did detect problems with our log-
link model, which suggests using a nonstandard link function
instead. An estimator that attempts to relax the limitation of
prespecifying a link or distributional family is the extended GLM
approach termed extended estimating equations (EEE). [56]. We
did expect that the mean GLM estimate ($5,069) based on 111
person-years would be higher than the disease-speciﬁc estimate
($6884) based on 105 person-years. This could indeed be due to a
misspeciﬁcation problem with the regression model.
The reliability of regression models is dependent on the model
used. Recently, an MEPS study compared six econometric models
and based their reported model on goodness-of-ﬁt statistics—root
mean square error, mean absolute error, and the scale-free Theil’s
statistic (15]. The conventional wisdom is that no single model is best
for all cases, but comprehensive model checking is recommended
[73]. With the MEPS, future regression-based analyses can include a
plethora of models in STATA because code has been made freely
available and textbooks become available to compare models in
terms of a host of performance parameters such as mean absolution
prediction error and the Copas test [74]. It is also possible that a “gold
standard” approach of constructing a matched cohort and then
performing a regression analysis could be used for the MEPS data
[1]. This suggestion has recently been implemented for asthma [5].Conclusions
We report a range of estimates of the direct medical expenditures
of HNC based on four established approaches using the MEPS.
Indeed, many additional estimates can be generated with match-
ing and regression methods. As models become increasingly
more sophisticated, however, the barriers for policymakers of
accessing COI estimates and using them in an intelligent fashion
to inform policy will increase. While it is accepted that policy-
makers are not the only audience for such studies, the value of a
consensus on methods seems evident. In the absence of this, the
caveat emptor will increasingly ring hollow and the value of such
studies shall increasingly be called into question, especially in an
emotive topic such as human papilloma virus vaccination of boys
owing to the economic burden of treating subsequent cancers.
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